Strategic Partnerships ARPA-H funded programs and cystic fibrosis foundation investments signal strong potential for collaboration with government research initiatives and patient advocacy groups. Leverage these ecosystems to position Breath Biopsy as a scalable platform for early cancer and infectious disease diagnostics, enabling partner-funded validation studies and co-development opportunities.

Clinical Validation Recent investments and awards targeted at cancer screening and CF-related infections indicate demand for validated, non-invasive diagnostic tools. Target hospitals, academic medical centers, and pharma as partners for large-scale clinical studies to demonstrate real-world performance and drive adoption in precision medicine pipelines.

Diversified Revenue Multiple funding streams and collaboration models exist, including equity investments and funded research partnerships. Explore sponsored studies, license-to-operate deals for Breath Biopsy technology, and potential service contracts with pharma and academic centers to diversify revenue beyond product sales.

Key Markets Focus on respiratory, liver, cancer, and digestive health diagnostic applications where non-invasive breath tests can streamline screening and monitoring. Position for payer conversations by highlighting cost-savings targets and improved outcomes through early detection and longitudinal monitoring solutions.

Customer Access OMED Health and Breath Biopsy services are already available to academic, clinical, and pharma partners. Use these existing channels to propose pilot programs, CRO-style diagnostic development services, and co-branded studies to accelerate partner onboarding and evidence generation.